Correction to: Real-world characteristics, treatment experiences and corticosteroid utilisation of patients treated with tofacitinib for moderate to severe ulcerative colitis
BMC Gastroenterol
.
2022 Jul 26;22(1):356.
doi: 10.1186/s12876-022-02298-7.
Authors
Michael V Chiorean
1
,
Jessica R Allegretti
2
,
Puza P Sharma
3
,
Benjamin Chastek
4
,
Leonardo Salese
5
,
Elizabeth J Bell
6
,
Jesse Peterson-Brandt
6
,
Joseph C Cappelleri
7
,
Xiang Guo
5
,
Nabeel Khan
8
Affiliations
1
Swedish Medical Center, Seattle, WA, USA.
2
Brigham and Women's Hospital, Boston, MA, USA.
3
Pfizer Inc, New York, NY, USA.
4
Optum Life Sciences, HEOR, 11000 Optum Circle, Eden Prairie, MN, 55344, USA.
[email protected]
.
5
Pfizer Inc, Collegeville, PA, USA.
6
Optum Life Sciences, HEOR, 11000 Optum Circle, Eden Prairie, MN, 55344, USA.
7
Pfizer Inc, Groton, CT, USA.
8
Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
PMID:
35883049
PMCID:
PMC9327372
DOI:
10.1186/s12876-022-02298-7
No abstract available
Publication types
Published Erratum